UCA1 was reported to play an oncogenic role in CCAAT/enhancer-binding protein-α dominant negative isoform (C/EBPα-p30)-positive AMLs [37] and to be involved in chemoresistance of AML cells towards daunorubicin-based therapies [38]. This evidence concerns the gene UCA1 and acute myeloid leukemia.